Hiperhomocisteínemia ‐ Uma ameaça oculta da doença inflamatória intestinal?

Joana Magalhães, Bruno Rosa, Maria João Moreira, Mara Barbosa, Ana Rebelo, Sílvia Leite, José Cotter
{"title":"Hiperhomocisteínemia ‐ Uma ameaça oculta da doença inflamatória intestinal?","authors":"Joana Magalhães,&nbsp;Bruno Rosa,&nbsp;Maria João Moreira,&nbsp;Mara Barbosa,&nbsp;Ana Rebelo,&nbsp;Sílvia Leite,&nbsp;José Cotter","doi":"10.1016/j.jpg.2014.01.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Several recent studies have reported increased homocysteine levels in Inflammatory Bowel Disease (IBD). Hyperhomocysteinemia (hHcys) has been proved to be an independent risk factor for coronary artery disease, arterial and venous thrombosis, making it an interesting candidate as a pathogenic link in IBD. The aims of this study were to assess the prevalence of hHcys in patients with IBD and to investigate the relation between homocysteine levels and its main determinants.</p></div><div><h3>Material and methods</h3><p>Single‐center prospective study including 47 patients (29 patients with Crohn's disease and 18 patients with Ulcerative Colitis) consecutively observed in a consultation of Inflammatory Bowel Disease. Blood samples were obtained from all patients following fasting and these samples were used for determination of C reactive protein, folic acid, vitamin B<sub>12</sub> and homocysteine levels. Clinical data recorded from disease onset to the time of the homocysteine assay were analysed. Association between categorical variables and comparisons of means were tested by Fisher exact test and Student t test, respectively. To identify predictive factors of hHcys in patients with IBD, a linear regression analysis was applied. The statistical level of significance was established at 5%. Statistical analysis was performed with SPSS (version 18.0).</p></div><div><h3>Results</h3><p>In our series, 10.6% of IBD patients were found to have hHcys. Five patients (10.6%) had a previous history of thromboembolism. Compared to patients with normal homocysteine levels, those with hHcys were younger (<em>p</em> &lt;<!--> <!-->0.001), had lower levels of folic acid (<em>p</em> &lt;<!--> <!-->0.001), and had a lower illness duration (<em>p</em> &lt;<!--> <!-->0.001). In patients with hHcys there also were a statistically significant difference according to smoking status (<em>p</em> <!-->&lt;<!--> <!-->0.001). Linear regression analysis to predict homocysteine levels based on age, illness duration, vitamin B<sub>12</sub> and folic acid levels was significative (<em>p</em> <!-->=<!--> <!-->0.001) and explain 37% of the variance found in homocysteine levels of this sample. The level of folic acid was a significant predictor (<em>p</em> <!-->=<!--> <!-->0.01) of hHcys.</p></div><div><h3>Conclusion</h3><p>Hyperhomocysteinemia is a common phenomenon in patients with IBD. Preventive measures could focus on reversible risk factors correlated with hHcys, such as cessation of smoking and correction of vitamin deficiencies.</p></div>","PeriodicalId":100572,"journal":{"name":"GE Jornal Português de Gastrenterologia","volume":"21 4","pages":"Pages 155-160"},"PeriodicalIF":0.0000,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jpg.2014.01.005","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GE Jornal Português de Gastrenterologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0872817814000071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives

Several recent studies have reported increased homocysteine levels in Inflammatory Bowel Disease (IBD). Hyperhomocysteinemia (hHcys) has been proved to be an independent risk factor for coronary artery disease, arterial and venous thrombosis, making it an interesting candidate as a pathogenic link in IBD. The aims of this study were to assess the prevalence of hHcys in patients with IBD and to investigate the relation between homocysteine levels and its main determinants.

Material and methods

Single‐center prospective study including 47 patients (29 patients with Crohn's disease and 18 patients with Ulcerative Colitis) consecutively observed in a consultation of Inflammatory Bowel Disease. Blood samples were obtained from all patients following fasting and these samples were used for determination of C reactive protein, folic acid, vitamin B12 and homocysteine levels. Clinical data recorded from disease onset to the time of the homocysteine assay were analysed. Association between categorical variables and comparisons of means were tested by Fisher exact test and Student t test, respectively. To identify predictive factors of hHcys in patients with IBD, a linear regression analysis was applied. The statistical level of significance was established at 5%. Statistical analysis was performed with SPSS (version 18.0).

Results

In our series, 10.6% of IBD patients were found to have hHcys. Five patients (10.6%) had a previous history of thromboembolism. Compared to patients with normal homocysteine levels, those with hHcys were younger (p < 0.001), had lower levels of folic acid (p < 0.001), and had a lower illness duration (p < 0.001). In patients with hHcys there also were a statistically significant difference according to smoking status (p < 0.001). Linear regression analysis to predict homocysteine levels based on age, illness duration, vitamin B12 and folic acid levels was significative (p = 0.001) and explain 37% of the variance found in homocysteine levels of this sample. The level of folic acid was a significant predictor (p = 0.01) of hHcys.

Conclusion

Hyperhomocysteinemia is a common phenomenon in patients with IBD. Preventive measures could focus on reversible risk factors correlated with hHcys, such as cessation of smoking and correction of vitamin deficiencies.

高同型半胱氨酸血症——炎症性肠病的潜在威胁?
最近的几项研究报道了炎症性肠病(IBD)中同型半胱氨酸水平升高。高同型半胱氨酸血症(hHcys)已被证明是冠状动脉疾病、动脉和静脉血栓形成的独立危险因素,使其成为IBD的一个有趣的致病环节。本研究的目的是评估hcys在IBD患者中的患病率,并调查同型半胱氨酸水平与其主要决定因素之间的关系。材料和方法单中心前瞻性研究,包括47例患者(29例克罗恩病患者和18例溃疡性结肠炎患者),在炎症性肠病会诊期间连续观察。所有患者在禁食后采集血样,用于测定C反应蛋白、叶酸、维生素B12和同型半胱氨酸水平。分析从发病到进行同型半胱氨酸测定的临床资料。分类变量之间的相关性和均值比较分别采用Fisher精确检验和Student t检验。为了确定IBD患者hHcys的预测因素,采用线性回归分析。统计学显著性水平为5%。采用SPSS(18.0)软件进行统计学分析。结果10.6%的IBD患者有hcys。5例患者(10.6%)既往有血栓栓塞史。与同型半胱氨酸水平正常的患者相比,hHcys患者更年轻(p <0.001),叶酸水平较低(p <0.001),且病程较短(p <0.001)。在hcys患者中,吸烟状况的差异也有统计学意义(p <0.001)。基于年龄、病程、维生素B12和叶酸水平预测同型半胱氨酸水平的线性回归分析具有显著性(p = 0.001),并解释了该样本中发现的37%的同型半胱氨酸水平方差。叶酸水平是hhys的显著预测因子(p = 0.01)。结论高同型半胱氨酸血症是IBD患者的常见现象。预防措施可侧重于与卫生保健相关的可逆风险因素,如戒烟和纠正维生素缺乏症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信